SCEMBLIX Drug Patent Profile

When do Scemblix patents expire, and when can generic versions of Scemblix launch?

Scemblix is a drug marketed by Novartis and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-one patent family members in fifty countries.

The generic ingredient in SCEMBLIX is asciminib hydrochloride. One supplier is listed for this compound. Additional details are available on the asciminib hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Scemblix

Scemblix was eligible for patent challenges on October 29, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 14, 2040. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for SCEMBLIX

International Patents:	91
US Patents:	4
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for SCEMBLIX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SCEMBLIX	Tablets	asciminib hydrochloride	100 mg	215358	5	2025-11-13

US Patents and Regulatory Information for SCEMBLIX

SCEMBLIX is protected by four US patents and nine FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 11,407,735.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-003	Apr 18, 2024		RX	Yes	Yes	11,407,735			Y
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-003	Apr 18, 2024		RX	Yes	Yes
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-001	Oct 29, 2021		RX	Yes	No	12,252,479
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-001	Oct 29, 2021		RX	Yes	No
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-001	Oct 29, 2021		RX	Yes	No	11,407,735			Y

International Patents for SCEMBLIX

When does loss-of-exclusivity occur for SCEMBLIX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

European Patent Office

Israel

Japan

Mexico

South Korea

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SCEMBLIX around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2020276701	Crystalline forms of N-(4-(chlorodifluoromethoxy)phenyl)-6-((3R)-3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
Brazil	112021022712	Formas cristalinas de n-[4-(clorodifluorometóxi)fenil]-6-[(3r)-3-hidroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida
Canada	3139812	FORMES CRISTALLINES DE N-[4- (CHLORODIFLUOROMETHOXY) PHENYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDE (CRYSTALLINE FORMS OF N-[4-(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDE)
Chile	2021003011	Formas cristalinas de n–[4–(clorodifluorometoxi)fenil]–6–[(3r)–3–hidroxipirrolidin–1–il]–5–(1h–pirazol–5–il)piridina–3–carboxamida
China	114144232	N-[4-(氯二氟甲氧基)苯基]-6-[(3R)-3-羟基吡咯烷-1-基]-5-(1H-吡唑-5-基)吡啶-3-甲酰胺的结晶形式 (Crystalline forms of n-[4-(chlorodifluoromethoxy) phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl) pyridine-3-carboxamide)

Supplementary Protection Certificates for SCEMBLIX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2861579	LUC00287	Luxembourg		PRODUCT NAME: ASCIMINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, SUCH AS ASCIMINIB HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/22/1670 20220826
2861579	202240042	Slovenia		PRODUCT NAME: ASCIMINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AS IT IS ASCIMINIB HYDROCHLORIDE; NATIONAL AUTHORISATION NUMBER: EU/1/22/1670; DATE OF NATIONAL AUTHORISATION: 20220825; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2861579	2022C/548	Belgium		PRODUCT NAME: ASCIMINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN, ZOALS ASCIMINIB HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/22/1670 20220826
2861579	2290039-3	Sweden		PRODUCT NAME: ASCIMINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, SUCH AS ASCIMINIB HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1670 20220826
2861579	C02861579/01	Switzerland		PRODUCT NAME: ASCIMINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68441 09.06.2022

Last updated: July 27, 2026

SCEMBLIX (asciminib) investment scenario and IP/regulatory fundamentals analysis

SCEMBLIX (asciminib) is a targeted BCR-ABL1 inhibitor positioned in chronic myeloid leukemia and Philadelphia chromosome–positive diseases with a potential “late-patent” and “later-line” investment profile driven by: (1) patent durability versus multiple generic entry vectors, (2) whether the clinical label expands faster than competitor mechanisms, and (3) the probability of sustained payer adoption as pricing and sequencing mature. The investment case depends on pipeline breadth (phase progression and label expansion), patent estate strength around the asciminib molecule and its key dosing/combination constructs, and the FDA exclusivity timeline behind first-approval and major label updates.

This document is limited to IP, regulatory, and investment-fundamentals structures. No commercial revenue forecasts are provided without verified, source-backed figures.

---

What is SCEMBLIX (asciminib) and what market need does it address?

Quick read (investment framing): SCEMBLIX targets the ABL myristoyl pocket, differentiating from ATP-site TKI classes. The practical value proposition is durable kinase inhibition in subsets where resistance or intolerance limits outcomes with prior TKIs, which can translate into defensible sequencing and preference if real-world durability matches clinical endpoints.

Indication and line-of-therapy positioning

• The core investment question is whether asciminib becomes a standard sequencing option (front-line or earlier-line) or stays a late-line salvage therapy.
• Late-line positioning usually supports higher price but smaller TAM; earlier-line adoption expands TAM but raises head-to-head evidence requirements.

Comparator classes

• ATP-competitive BCR-ABL TKIs (imatinib class, dasatinib, nilotinib, bosutinib, ponatinib).
• The investment risk is mechanism convergence: if ATP-site TKIs regain share via earlier use, tolerability, or combination regimens, asciminib faces sequencing pressure even with distinct binding.

---

What patents protect asciminib (SCEMBLIX) and how strong is the patent estate?

Featured snippet answer: A defensible investment profile requires (1) composition-of-matter coverage on asciminib, (2) method-of-use claims mapped to the marketed indication and dosing, and (3) formulation/manufacturing claims that block “workaround” generics and non-licensed ANDAs.

Patent estate components investors track

• Composition of matter (drug substance).
• Salt, polymorph, and solid-state forms (if any).
• Pharmaceutical compositions and formulation processes (film coating, tablets, capsules, granulation, particle size).
• Method-of-use: dosing regimens and patient populations defined by biomarkers or prior therapy.
• Combination therapy claims (if label expansions include pairings).

How to assess “strength” for investors

Key signals:

1. Claim adjacency to the commercial label (if method claims match real-world prescribing).
2. Remaining life on key claims at the expected generic entry window.
3. Sustained USPTO/ETR validation (continuations, reexams, PTAB posture).
4. Litigation history (if any Paragraph IV campaigns have targeted asciminib or if settlements reflect expected generic timelines).

Patent risk categories

• Early expiration on the most commercially relevant claim sets (method-of-use often expires earlier than composition claims).
• Design-around via salts/solid forms if only limited claim coverage exists.
• Non-infringing dosing if claims are narrow and regulators accept off-label shifts.

---

When does SCEMBLIX lose exclusivity, and what exclusivity layers control generic timing?

Featured snippet answer: Generic and biosimilar entry timing is usually governed by a stack: Orange Book patent expirations (plus any statutory patent term adjustments), FDA exclusivity (New Chemical Entity and/or data exclusivity), and any pediatric exclusivity extensions tied to later submissions.

Exclusivity vs patents: different clocks

• Statutory/regulatory exclusivity protects against FDA approval of an application relying on the sponsor’s data.
• Orange Book-listed patents determine when ANDA/505(b)(2) products can be approved and launched, including risk of injunction or “entry at risk” under Paragraph IV.

What investors should model

• The earliest date any Orange Book-listed patent expires.
• The “last-to-expire” patent for the marketed dosage form and indication.
• Whether label expansions trigger new exclusivity (rare, but possible via supplemental NDA pathways).
• Whether any patents are subject to regulatory exclusivity stacking or pediatric exclusivity.

---

What is the Orange Book status of SCEMBLIX (asciminib), and how many listed patents cover it?

Featured snippet answer: Investors should anchor to the Orange Book listing count and structure: number of composition vs method vs formulation/manufacturing patents, plus listed expirations and statutory adjustments.

Orange Book-driven decision points

• Coverage depth by dosage form (tabs/caps) and strength.
• Whether “use patents” are listed broadly across indications or only for a narrow initial label.
• Whether there are multiple “expiration cliffs” that shape generic launch waves.

Why “patent count” matters less than coverage breadth

A higher count can signal stronger protection or simply a layered but fragmented set of claims. The key is whether the claims are enforceable and overlap with the exact FDA-approved use and product attributes.

---

Are there Paragraph IV challenges against SCEMBLIX, and which companies have targeted it?

Featured snippet answer: Paragraph IV litigation determines practical launch timing more than patents alone because it drives settlement calendars and injunction risk.

Investment-grade indicators to track

• Existence of ANDA Paragraph IV filings referencing asciminib.
• Filing-to-dispute timelines (first notice letters, court dockets, motions).
• Settlement terms: “switch date,” license scope, and launch restrictions.

How to map competitor behavior

• If multiple challengers file early, it can signal belief in weak patent coverage and lower settlement value.
• If a single challenger files and then settles quickly, it can signal expectation of a relatively strong injunction posture.

---

What patent litigation affects SCEMBLIX, and what are the outcomes investors need?

Featured snippet answer: Dockets and claim construction outcomes drive real risk. A strong investment profile shows (1) sustained validity/infringement findings, (2) limited adverse rulings, and (3) settlements that push generic entry to a late calendar.

Litigation structures that matter

• Case style: patent infringement vs declaratory judgment actions.
• Claim scope: whether the relevant claims survive summary judgment.
• Whether enjoined products are narrow “design-around” versions.

Settlement patterns that change investment math

• License-only settlements can allow earlier launch without full court outcomes.
• “No-admission” settlements can still set effective entry timelines via commercial agreements.

---

Does SCEMBLIX face biosimilar risk, or is the primary threat only generic substitution?

Featured snippet answer: SCEMBLIX is a small molecule; it does not face biosimilar pathways. The primary regulatory competition risk is generic substitution via ANDAs and 505(b)(2) products.

What investors should model instead

• Generic substitution at pharmacy and PBM level after regulatory approval.
• Switching behavior in hematology practices once generics appear.
• Whether prescribers require brand continuity for efficacy/durability.

---

How do formulation and method-of-use patents for SCEMBLIX affect generic entry?

Featured snippet answer: Formulation and method-of-use claims affect generic entry if they:

1. require non-standard manufacturing steps or unique solid-state properties, or
2. define dosing/eligibility in a way that a generic cannot replicate without crossing infringement.

Formulation barriers

• Particle size, polymorph control, and dissolution profile can be relevant if claims cover those features.
• If manufacturing claims exist, generic entrants may still need licensed process know-how.

Method-of-use barriers

• Claims tied to prior TKI failure or biomarker-defined patient populations can constrain “label parity” design.
• If a generic cannot carve out the protected patient population, it faces infringement risk.

---

How does SCEMBLIX compare with other BCR-ABL inhibitors on competitive and IP grounds?

Featured snippet answer: Asciminib’s differentiation is binding-site modality, but investment outcomes still track whether it gains durable line-of-therapy placement versus ATP-site TKIs and other combination approaches.

Mechanism differentiation vs payer adoption

• Mechanism difference can win clinical use, but adoption hinges on:
  • sustained response duration,
  • toxicity management,
  • and cost-effectiveness vs generic erosion of older TKIs.

Competitive IP interplay

• Older ATP-site TKIs largely face generic competition, compressing pricing and making it harder for newer agents to justify premium without clear differentiation.
• Asciminib benefits if it avoids “me-too” economics and secures protected positioning via durable data packages and label expansion.

---

What is the commercial investment scenario for SCEMBLIX: growth levers and revenue exposure?

Featured snippet answer: SCEMBLIX’s revenue exposure is driven by a small set of controllable levers: label expansion, combination strategy, resistance-management durability, and pricing power sustained through patent coverage.

Growth levers

• Earlier-line adoption if comparative trials support use before late salvage.
• Combination therapy approvals if clinical endpoints justify add-on value.
• Expanded biomarkers or patient subsets through supplemental label pathways.

Downside levers

• Faster generic substitution of competing agents forcing pricing compression and heightened cost-effectiveness scrutiny.
• Safety or tolerability signals limiting prescribing intensity.
• Competitive encroachment by agents with stronger evidence in earlier lines.

---

What regulatory milestones and FDA pathway risks matter for SCEMBLIX?

Featured snippet answer: Investment risk concentrates on regulatory timing, label scope, and the sponsor’s ability to convert clinical evidence into market-access friendly labeling.

Milestones investors track

• FDA approval date, initial label, and subsequent supplemental approvals.
• Chemistry, manufacturing, controls stability updates that can affect supply confidence.
• Postmarketing requirements that can delay label expansions or trigger operational costs.

---

What generic entry risks exist for SCEMBLIX under ANDA pathways?

Featured snippet answer: Generic entry risk peaks at Orange Book patent expirations plus the end of applicable data exclusivity, tempered by Paragraph IV/injunction dynamics.

Entry scenarios

• Low-risk entry: strong patent coverage survives; challengers settle or are enjoined.
• High-risk entry: early claim invalidity findings or weak infringement defenses; challengers settle with early launch.
• Staggered entry: different strengths/dosage forms or method-of-use carve-outs lead to multiple partial launches.

Operational barriers

• If manufacturing quality attributes are tightly linked to efficacy, generics may face uptake friction even after approval.

---

Key Takeaways

• SCEMBLIX’s investment profile is defined by the interaction of Orange Book patent coverage and FDA exclusivity timing, not by clinical efficacy alone.
• Generic competition is the primary threat; biosimilar risk does not apply because asciminib is a small molecule.
• Patent estate strength must be evaluated across composition, method-of-use, and formulation/manufacturing constructs that map tightly to the FDA-approved label.
• Litigation and Paragraph IV posture are often the decisive timing drivers for real-world launch and settlement calendars.
• Commercial upside is tied to label expansion and sequencing wins; downside risk is payer-driven pricing compression as competitors become fully generic and asciminib’s premium requires sustained clinical differentiation.

---

FAQs

1) How do Orange Book “use” patents change ANDA paragraph IV strategy for SCEMBLIX?
They can prevent full generic labeling parity without infringement exposure unless the ANDA can support a carve-out or non-infringing patient/dosing approach.

2) What factors determine whether SCEMBLIX faces multiple generic launch waves instead of one?
Different expirations across dosage forms/strengths and differentiated claim sets (composition vs method vs formulation) can create staggered approval and launch dates.

3) What settlement terms typically indicate lower launch risk for SCEMBLIX brand protection?
Longer “switch” dates, broader license scope limits, and provisions restricting launch timing and labeling can delay entry even when patents are challenged.

4) Does switching to a generic of asciminib affect treatment continuity in CML practice?
Adoption risk depends on prescriber and payer confidence in bioequivalence plus real-world response consistency; brand continuity can remain preferred if durability is valued.

5) What supplemental label expansions for asciminib most affect the investment horizon?
Those that add new patient populations, earlier-line use, or combination regimens tend to extend commercial relevance and increase the probability that existing method-of-use and dosing patents remain in play.

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
3. United States Patent and Trademark Office. (n.d.). Patent Public Search. https://ppubs.uspto.gov/